These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 32187384)

  • 1. Test trial of spike-in immunoglobulin heavy-chain (IGH) controls for next generation sequencing quantification of minimal residual disease in acute lymphoblastic leukaemia.
    Giusti GNN; Jotta PY; Lopes CO; Ganazza MA; de Azevedo AC; Brandalise SR; Meidanis J; Yunes JA
    Br J Haematol; 2020 May; 189(4):e150-e154. PubMed ID: 32187384
    [No Abstract]   [Full Text] [Related]  

  • 2. A clinical perspective on immunoglobulin heavy chain clonal heterogeneity in B cell acute lymphoblastic leukemia.
    Fries C; Burack WR
    Leuk Res; 2018 Dec; 75():15-22. PubMed ID: 30445235
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Minimal residual disease detection by next-generation sequencing of different immunoglobulin gene rearrangements in pediatric B-ALL.
    Chen H; Gu M; Liang J; Song H; Zhang J; Xu W; Zhao F; Shen D; Shen H; Liao C; Tang Y; Xu X
    Nat Commun; 2023 Nov; 14(1):7468. PubMed ID: 37978187
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detection of Immunoglobulin Heavy Chain Gene Clonality by Next-Generation Sequencing for Minimal Residual Disease Monitoring in B-Lymphoblastic Leukemia.
    Shin S; Hwang IS; Kim J; Lee KA; Lee ST; Choi JR
    Ann Lab Med; 2017 Jul; 37(4):331-335. PubMed ID: 28445014
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-throughput sequencing of immunoglobulin heavy chain for minimal residual disease detection in B-lymphoblastic leukemia.
    Correia RP; Puga RD; Muto NH; Lee MLM; Torres DC; Hassan R; Bacal NS; Hamerschlak N; Campregher PV
    Int J Lab Hematol; 2021 Aug; 43(4):724-731. PubMed ID: 33393719
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Application of the Euro Clonality next-generation sequencing-based marker screening approach to detect immunoglobulin heavy chain rearrangements in mantle cell lymphoma patients: first data from the Fondazione Italiana Linfomi MCL0208 trial.
    Genuardi E; Romano G; Beccuti M; Alessandria B; Mannina D; Califano C; Rota Scalabrini D; Cortelazzo S; Ladetto M; Ferrero S; Calogero RA; Cordero F
    Br J Haematol; 2021 Jul; 194(2):378-381. PubMed ID: 34002365
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-throughput sequencing in acute lymphoblastic leukemia: Follow-up of minimal residual disease and emergence of new clones.
    Salson M; Giraud M; Caillault A; Grardel N; Duployez N; Ferret Y; Duez M; Herbert R; Rocher T; Sebda S; Quief S; Villenet C; Figeac M; Preudhomme C
    Leuk Res; 2017 Feb; 53():1-7. PubMed ID: 27930944
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Digital droplet PCR and next-generation sequencing refine minimal residual disease monitoring in acute lymphoblastic leukemia.
    Della Starza I; De Novi LA; Santoro A; Salemi D; Tam W; Cavalli M; Menale L; Soscia R; Apicella V; Ilari C; Vitale A; Testi AM; Inghirami G; Chiaretti S; Foà R; Guarini A
    Leuk Lymphoma; 2019 Nov; 60(11):2838-2840. PubMed ID: 31050551
    [No Abstract]   [Full Text] [Related]  

  • 9. Detection of minimal residual disease in B lymphoblastic leukemia by high-throughput sequencing of IGH.
    Wu D; Emerson RO; Sherwood A; Loh ML; Angiolillo A; Howie B; Vogt J; Rieder M; Kirsch I; Carlson C; Williamson D; Wood BL; Robins H
    Clin Cancer Res; 2014 Sep; 20(17):4540-8. PubMed ID: 24970842
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Next-Generation Sequencing for Minimal Residual Disease Surveillance in Acute Lymphoblastic Leukemia: An Update.
    Reyes-Barron C; Burack WR; Rothberg PG; Ding Y
    Crit Rev Oncog; 2017; 22(5-6):559-567. PubMed ID: 29604931
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Standardized next-generation sequencing of immunoglobulin and T-cell receptor gene recombinations for MRD marker identification in acute lymphoblastic leukaemia; a EuroClonality-NGS validation study.
    Brüggemann M; Kotrová M; Knecht H; Bartram J; Boudjogrha M; Bystry V; Fazio G; Froňková E; Giraud M; Grioni A; Hancock J; Herrmann D; Jiménez C; Krejci A; Moppett J; Reigl T; Salson M; Scheijen B; Schwarz M; Songia S; Svaton M; van Dongen JJM; Villarese P; Wakeman S; Wright G; Cazzaniga G; Davi F; García-Sanz R; Gonzalez D; Groenen PJTA; Hummel M; Macintyre EA; Stamatopoulos K; Pott C; Trka J; Darzentas N; Langerak AW;
    Leukemia; 2019 Sep; 33(9):2241-2253. PubMed ID: 31243313
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is Next-Generation Sequencing the way to go for Residual Disease Monitoring in Acute Lymphoblastic Leukemia?
    Kotrova M; Trka J; Kneba M; Brüggemann M
    Mol Diagn Ther; 2017 Oct; 21(5):481-492. PubMed ID: 28452038
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-throughput VDJ sequencing for quantification of minimal residual disease in chronic lymphocytic leukemia and immune reconstitution assessment.
    Logan AC; Gao H; Wang C; Sahaf B; Jones CD; Marshall EL; Buño I; Armstrong R; Fire AZ; Weinberg KI; Mindrinos M; Zehnder JL; Boyd SD; Xiao W; Davis RW; Miklos DB
    Proc Natl Acad Sci U S A; 2011 Dec; 108(52):21194-9. PubMed ID: 22160699
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Minimal residual disease quantification in childhood acute lymphoblastic leukemia by real-time polymerase chain reaction using the SYBR green dye.
    Li AH; Forestier E; Rosenquist R; Roos G
    Exp Hematol; 2002 Oct; 30(10):1170-7. PubMed ID: 12384148
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monitoring of minimal residual disease in early T-cell precursor acute lymphoblastic leukaemia by next-generation sequencing.
    Pan X; Nariai N; Fukuhara N; Saito S; Sato Y; Katsuoka F; Kojima K; Kuroki Y; Danjoh I; Saito R; Hasegawa S; Okitsu Y; Kondo A; Onishi Y; Nagami F; Kiyomoto H; Hozawa A; Fuse N; Nagasaki M; Shimizu R; Yasuda J; Harigae H; Yamamoto M
    Br J Haematol; 2017 Jan; 176(2):318-321. PubMed ID: 26822323
    [No Abstract]   [Full Text] [Related]  

  • 16. [Assessment of minimal residual disease in adult patients with B-lineage acute lymphoblastic leukemia using rearranged immunoglobulin loci detection].
    Yao L; Chen ZX; Cen JN; Liu H; He J; Wu DP
    Zhonghua Xue Ye Xue Za Zhi; 2010 Jul; 31(7):433-7. PubMed ID: 21122394
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical pilot study on microfluidic automation of IGH-VJ library preparation for next generation sequencing.
    Hess JF; Kotrová M; Fricke B; Songia S; Rigamonti S; Cavagna R; Tosi M; Paust N; Langerak AW; Spinelli O; Cazzaniga G; Brüggemann M; Hutzenlaub T
    Clin Chem Lab Med; 2024 Jun; 62(7):e164-e167. PubMed ID: 38153095
    [No Abstract]   [Full Text] [Related]  

  • 18. Clinical benefit of a high-throughput sequencing approach for minimal residual disease in acute lymphoblastic leukemia.
    Wright G; Watt E; Inglott S; Brooks T; Bartram J; Adams SP
    Pediatr Blood Cancer; 2019 Aug; 66(8):e27787. PubMed ID: 31034760
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Dynamic monitoring of minimal residual disease in acute lymphoid leukemia].
    Shan SL; Xing HY; Tian Z; Tang KJ; Rao Q; Wang M; Wang JX
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Dec; 19(6):1404-8. PubMed ID: 22169292
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Considerations for monitoring minimal residual disease using immunoglobulin clonality in patients with precursor B-cell lymphoblastic leukemia.
    Jo I; Chung NG; Lee S; Kwon A; Kim J; Choi H; Jang W; Kim S; Lee JW; Yoon JH; Cho B; Han K; Kim Y; Kim M
    Clin Chim Acta; 2019 Jan; 488():81-89. PubMed ID: 30389459
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.